NCT06002945

Exploring Outcomes and Characteristics of Myasthenia Gravis 2

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.

Detailed description

The EXPLORE-MG2 (EXPLoring Outcomes and chaRactEristics of Myasthenia Gravis 2) study is a multi-center natural history study of myasthenia gravis (MG), a rare autoimmune disease characterized by weakness of the voluntary muscles. MG has a prevalence of approximately 14-40 per 100,000 people in the United States. There is no cure for MG, however, understanding the disease is crucial to pave the way for development of new therapies and a deeper mechanistic understanding to improve patient outcomes. Thus, EXPLORE-MG2 aims to accomplish comprehensive clinical phenotyping linked to bio-specimen collection in an effort to better understand disease characteristics and identify treatment predictive and responsive biomarkers. The primary purpose of this project is to create a network repository of data and biological samples to help researchers learn more about myasthenia gravis.

Conditions

• Myasthenia Gravis

Interventions

Type	Name	Description
OTHER	Blood sample	Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood

Timeline

• Start date: 2021-01-12
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2023-08-21
• Last updated: 2024-12-10

Locations

10 sites across 1 country: United States